Follow
Janos Szebeni
Janos Szebeni
Nanomedicine Research and Education Center, Semmelweis University
Verified email at seroscience.com
Title
Cited by
Cited by
Year
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties
SM Moghimi, J Szebeni
Progress in lipid research 42 (6), 463-478, 2003
16392003
Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity
J Szebeni
Toxicology 216 (2-3), 106-121, 2005
7162005
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions
A Chanan-Khan, J Szebeni, S Savay, L Liebes, NM Rafique, CR Alving, ...
Annals of Oncology 14 (9), 1430-1437, 2003
5612003
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention
J Szebeni, F Muggia, A Gabizon, Y Barenholz
Advanced drug delivery reviews 63 (12), 1020-1030, 2011
4982011
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals
GT Kozma, T Shimizu, T Ishida, J Szebeni
Advanced drug delivery reviews 154, 163-175, 2020
4432020
Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals
J Szebeni
Molecular immunology 61 (2), 163-173, 2014
4402014
PEGylated liposomes: immunological responses
M Mohamed, AS Abu Lila, T Shimizu, E Alaaeldin, A Hussein, HA Sarhan, ...
Science and Technology of Advanced Materials 20 (1), 710-724, 2019
4372019
Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study
J Szebeni, CR Alving, FM Muggia
JNCI: Journal of the National Cancer Institute 90 (4), 300-306, 1998
4281998
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
D Rampton, J Folkersen, S Fishbane, M Hedenus, S Howaldt, F Locatelli, ...
haematologica 99 (11), 1671, 2014
3332014
Poly (ethylene glycol) s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process
I Hamad, AC Hunter, J Szebeni, SM Moghimi
Molecular immunology 46 (2), 225-232, 2008
3072008
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives
D Shi, D Beasock, A Fessler, J Szebeni, JY Ljubimova, KA Afonin, ...
Advanced drug delivery reviews 180, 114079, 2022
3022022
F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins
M Basta, F Van Goor, S Luccioli, EM Billings, AO Vortmeyer, L Baranyi, ...
Nature medicine 9 (4), 431-438, 2003
2992003
Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20
Z Weiszhár, J Czúcz, C Révész, L Rosivall, J Szebeni, Z Rozsnyay
European journal of pharmaceutical sciences 45 (4), 492-498, 2012
2792012
Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome
J Szebeni, P Bedőcs, Z Rozsnyay, Z Weiszhár, R Urbanics, L Rosivall, ...
Nanomedicine: Nanotechnology, Biology and Medicine 8 (2), 176-184, 2012
2672012
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies
J Szebeni, L Baranyi, S Savay, J Milosevits, R Bunger, P Laverman, ...
Journal of liposome research 12 (1-2), 165-172, 2002
2532002
Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles
J Szebeni, CR Alving, L Rosivall, R Bünger, L Baranyi, P Bedöcs, M Tóth, ...
Journal of liposome research 17 (2), 107-117, 2007
2372007
Methylation of the phosphate oxygen moiety of phospholipid‐methoxy (polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin …
S Moein Moghimi, I Hamad, TL Andresen, K Jørgensen, J Szebeni, ...
The FASEB journal 20 (14), 2591-2593, 2006
2372006
Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and …
J Szebeni, JL Fontana, NM Wassef, PD Mongan, DS Morse, DE Dobbins, ...
Circulation 99 (17), 2302-2309, 1999
2361999
Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction
J Szebeni, L Baranyi, S Savay, M Bodo, DS Morse, M Basta, GL Stahl, ...
American Journal of Physiology-Heart and Circulatory Physiology 279 (3 …, 2000
2222000
Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents
J Szebeni
Critical Reviews™ in Therapeutic Drug Carrier Systems 18 (6), 2001
2052001
The system can't perform the operation now. Try again later.
Articles 1–20